Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient

TY - JOUR

T1 - Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient

AU - Doll, Sophia

AU - Kriegmair, Maximilian C.

AU - Santos, Alberto

AU - Wierer, Michael

AU - Coscia, Fabian

AU - Neil, Helen Michele

AU - Porubsky, Stefan

AU - Geyer, Philipp E.

AU - Mund, Andreas

AU - Nuhn, Philipp

AU - Mann, Matthias

N1 - © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2018

Y1 - 2018

N2 - Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.

AB - Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.

KW - case study

KW - clinical proteomics

KW - epigenetics

KW - mass spectrometry

KW - urachal carcinoma

U2 - 10.1002/1878-0261.12326

DO - 10.1002/1878-0261.12326

M3 - Journal article

C2 - 29901861

SN - 1574-7891

VL - 12

SP - 1296

EP - 1307

JO - Molecular Oncology

JF - Molecular Oncology

IS - 8

ER -